An optimized battery of eight antibodies that can distinguish mast gases at epithelial mesothelioma from adenocarcinoma

被引:46
作者
Brockstedt, U
Gulyas, M
Dobra, K
Dejmek, A
Hjerpe, A
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, Div Pathol, S-14186 Huddinge, Sweden
[2] Natl Inst Oncol, Div Cytopathol, Budapest, Hungary
[3] Univ Lund, Malmo Univ Hosp, Dept Clin Cytol & Pathol, Malmo, Sweden
关键词
malignant mesothelioma; immunocytochemistry; diagnosis;
D O I
10.1309/QHCA-8594-TA7P-0DVQ
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
An immunocytochemical battery comprising 9 antibodies specifically distinguishes 80% of the epithelial malignant mesotheliomas from adenocarcinomas. The discriminatory power of antibodies to calretinin was tested together with this battery to determine whether the performance thereby could be improved. The study comprises 119 mesotheliomas of epithelial or mixed phenotype and 57 adenocarcinoma metastases in the pleural cavity. The differences between the 2 groups were highly significant for all recorded parameters, but typical reactivity for all parameters was seen in only 6 (5.0%) of the 119 mesotheliomas. An algorithm based on stepwise logistic regression was used to interpret divergent reaction patterns. Most diagnostic information was obtained with 8 of the parameters studied. The resulting algorithm identified almost 90% of the mesotheliomas with high specificity. The battery can be performed in 2 steps: several adenocarcinomas first are diagnosed with a few antibodies, applying the rest of the battery on the remaining unresolved cases.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 21 条
[1]   MULTIPLE-MARKER IMMUNOHISTOCHEMICAL PHENOTYPES DISTINGUISHING MALIGNANT PLEURAL MESOTHELIOMA FROM PULMONARY ADENOCARCINOMA [J].
BROWN, RW ;
CLARK, GM ;
TANDON, AK ;
ALLRED, DC .
HUMAN PATHOLOGY, 1993, 24 (04) :347-354
[2]   DIFFUSE EPITHELIAL MESOTHELIOMA - A REVIEW OF THE ULTRASTRUCTURAL SPECTRUM [J].
DARDICK, I ;
JABI, M ;
MCCAUGHEY, WTE ;
DEODHARE, S ;
VANNOSTRAND, AWP ;
SRIGLEY, JR .
ULTRASTRUCTURAL PATHOLOGY, 1987, 11 (5-6) :503-533
[3]  
DEJMEK A, 1994, CANCER, V73, P464, DOI 10.1002/1097-0142(19940115)73:2<464::AID-CNCR2820730235>3.0.CO
[4]  
2-#
[5]   Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma [J].
Dejmek, A ;
Brockstedt, U ;
Hjerpe, A .
APMIS, 1997, 105 (11) :889-894
[6]   Calretinin: A novel immunocytochemical marker for mesothelioma [J].
Doglioni, C ;
Tos, APD ;
Laurino, L ;
Iuzzolino, P ;
Chiarelli, C ;
Celio, MR ;
Viale, G .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (09) :1037-1046
[7]  
Han AC, 1999, CANCER CYTOPATHOL, V87, P83, DOI 10.1002/(SICI)1097-0142(19990425)87:2<83::AID-CNCR7>3.0.CO
[8]  
2-S
[9]   Pleural mesothelioma in Sweden:: an analysis of the incidence according to the use of asbestos [J].
Järvholm, B ;
Englund, A ;
Albin, M .
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1999, 56 (02) :110-113
[10]  
Kho-Duffin J, 1999, DIAGN CYTOPATHOL, V20, P57, DOI 10.1002/(SICI)1097-0339(199902)20:2<57::AID-DC2>3.0.CO